We intend to use the net proceeds from this offering to continue the commercial launch of Vascepa® (icosapent ethyl) capsules in the MARINE indication, prepare for and commercially launch Vascepa in the ANCHOR indication, if approved, advance our REDUCE-IT cardiovascular outcomes trial, and for general corporate and working capital purposes.
The amounts and timing of these expenditures will depend on a number of factors, such as the success of the commercial launch of Vascepa, whether Vascepa is approved in the ANCHOR indication, the timing, scope, progress and results of our research and development efforts and the timing and progress of any partnering efforts. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds from this offering. Accordingly, we will retain broad discretion over the use of such proceeds.
Based on our current operating plans, we believe the proceeds from this financing, together with our current cash and cash equivalents, will be sufficient to fund our operations, including the potential need to expand our commercial presence following any approval of Vascepa in the ANCHOR indication, alone or in conjunction with commercial partners, through the end of 2014.
I'd like to see more detail on why they think this will carry them through 2014. I think this is probably correct, but would like more details. Does this assume no Anchor and only continuation of Script grown increases at some specified rate ? It's obviously a GIA basis.
Even though this was disappointing (with regard to timing, since I expected it to happen in the 4th Quarter not now) the share price drop will be limited to well above the micky D one QTR pdr level. Just not sure where it will dip... just opened the flood gates again for manipulation after it seemed to be settling down.... fk it (oops said it again).